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Abstract: Introduction Current clinical guidelines do not support the use of manual therapy(MT)
interventions for Fibromyalgia (FM) patients, despite evidence of positive biochemical,
mechanical and psychological effects, and the popularity of hands-on treatments
amongst patients. An optimal dose for MT has not been established; this may explain
the discrepancies found within the published literature. The aim of this systematic
review was to determine whether there is a dose response relationship for MT leading
to improvements in core domains of FM symptomology; Pain, Mood, Sleep, Global
Measure of Impact (Functional Status & Quality of Life). Methods We searched six
databases from 1990 to January 2018; studies were evaluated using the PEDro scale.
Within-group (ESd) and between-group (ESg) Effect Sizes were calculated. Results
We identified and screened 4012 articles, 12 articles were critically appraised. Overall,
there is moderate evidence that MT has positive effects on the four clinical outcomes
investigated. However, there was no consistent dose response relationship observed
across all studies. Conclusions A dose of approximately 45 minutes MT, five times per
week for three weeks, totalling 11 hours 15 mins, should be considered a baseline,
generic protocol for treatment delivery and research trials. Further research is
necessary to confirm domain specific, or patient specific optimal doses. Moderator
variables such as treatment time, frequency, duration; and MT type also need to be
explored to ensure optimal delivery of MT in future research and clinical care provision.
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Dear Dr Cambron 
 
I am submitting a manuscript for consideration of publication in the Journal of Bodywork and 
Movement Therapies.  The manuscript is entitled: 'Is there a dose response relationship 
between soft tissue manual therapies and clinical outcomes in Fibromyalgia?' 
It has not been published elsewhere, and has not been submitted simultaneously for 
publication elsewhere. 
This systematic review provides a unique approach to analyzing current literature relating to 
manual therapy treatments for Fibromyalgia.  The results support manual therapy 
interventions, and indicate the question of dose to be important, but not yet satisfactorily 
answered. We therefore recommended continuing enquiry for further researchers. 
 
Maintaining a research attention on manual therapy is essential if we are not to lose the 
opportunity to offer these approaches to patients.   
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Current clinical guidelines do not support the use of manual therapy (MT) 
interventions for Fibromyalgia (FM) patients, despite evidence of positive 
biochemical, mechanical and psychological effects, and the popularity of hands-
on treatments amongst patients.  An optimal dose for MT has not been 
established; this may explain the discrepancies found within the published 
literature. 
The aim of this systematic review was to determine whether there is a dose 
response relationship for MT leading to improvements in core domains of FM 
symptomology; Pain, Mood, Sleep, Global Measure of Impact (Functional 
Status & Quality of Life).  
 
Methods  
We searched six databases from 1990 to January 2018; studies were evaluated 
using the PEDro scale.  Within-group (ESd) and between-group (ESg) Effect 




We identified and screened 4012 articles, 12 articles were critically appraised.   
Overall, there is moderate evidence that MT has positive effects on the four 
clinical outcomes investigated.  However, there was no consistent dose response 
relationship observed across all studies.  
 
Conclusions  
A dose of approximately 45 minutes MT, three to five times per week, for three 
to five weeks, totalling 11 hours 15 mins, should be considered a baseline 
generic protocol for treatment delivery and research trials.  Further research is 
necessary to confirm domain specific, or patient specific optimal doses.  
Moderator variables such as treatment time, frequency, duration; and MT type 
also need to be explored to ensure optimal delivery of MT in future research and 








Definition and current management 
Fibromyalgia (FM) is an enigmatic disease with no clear aetiology, diagnostic 
markers, or best treatment protocol. Sufferers experience a myriad of symptoms 
including; widespread pain, fatigue, sleep disturbance, decreased function, 
affect disruption, and cognitive deficit. (Häuser 2018).  Due to its high, and 
reportedly increasing prevalence, 0.2 - 6.6% in the general population 
(Matsutani et al 2017); and the impact on Health Related Quality of Life 
(HRQOL), there is an associated economic burden for society and for the 
individual (Eijk-Hustings 2016).  
 
Despite FM being considered a problem of central sensitivity and maladapted 
central processing (Clauw 2014), it has been suggested that the periphery should 
not be ignored (Staud 2011).  Afferent input to the central nervous system via 
touch modalities could provide the stimulus for positive bioplastic adaption in 
the central nervous system.   Additionally, the main symptom which guides 
patient’s health seeking behaviour is muscle pain.  Localised treatments such as 
soft tissue manual therapies are often sought (Wahner-Roedler et al 2009), and 
have the potential to reduce ongoing nociceptive afferent input from altered 
tissue mechanics such as trigger points.  No ‘cure’ has been identified, therefore 
the aim of treatment is to provide symptomatic relief tailored to the individual.  
Recent evidence shows only modest improvements in outcomes (Thieme 2017).  
 
Guidelines and literature 
Clinical guidelines have supported active-engagement in self management 
through a multi-component approach including exercise, pharmacology and 
Cognitive Behaviour Therapy (CBT) (Häuser et al 2017).  Manual Therapies 
have not been supported; the revised 2015 EULAR (European League Against 
Rheumatism) guidelines gave a ‘weak against’ judgement for MT, despite their 
sub group analysis revealing ‘evidence of a positive effect with massage of 5 or 
more weeks duration’ (Macfarlane 2017).   Ablin et al (2013) evaluated recent 
guidelines with a specific focus on complementary and alternative therapies, 
their summary statement relating to MT was to discourage the use of ‘passive 
physical treatments e.g. massage “magic pill” ’. Physiological evidence 
however has supported the therapeutic potential for MT (Field 2010 & 2014, 
Holey & Dixon 2014, Liptan 2010).  
 
Authors have suggested insufficient numbers of high quality studies and  
heterogeneity found between trials, as reasons for the lack of support for MT   
(Terry et al 2012, Terhorst et al 2011).   The variety of interventions, and  
dosing patterns reported in previous reviews shows a lack of standardization  
(Yuan et al 2015, Kalichman 2010, Terhorst et al 2011).  Without  
standardisation of dose, it is possible that even with the ‘right intervention’ ‘the  
wrong duration will skew research toward a negative outcome’ (Wallden 2015).   
Crawford (2016) has suggested; ‘Drug trials undergo systematic phase trials to  
determine consistent and adequate dosing, massage trials do not carry out such  
processes and often do not provide rationale for dose related variables’.    
Sherman et al (2014) suggested that inconclusive reviews investigating efficacy  
of massage for chronic neck pain resulted from inadequate doses of the  
intervention, their 6-arm dosing trial showed significant dose-dependant  
benefits, indicating the relevance of dosage. 
 
Therapeutic action of MT 
Manual therapies using hands on touch to manipulate bodily tissues, can be 
directed at soft tissue or joint.  Within the soft tissue therapies, massage has 
received the most exposure in the literature.  Other forms of soft tissue MT have 
also been investigated in relation to treatment for FM; including Myofascial 
release (MFR), Cranial Sacral Therapy (CST), Fasciotherapy, Connective 
Tissue Massage (CTM), Manual Lymphatic Drainage Therapy (MLDT).  All 
soft tissue MT’s can usually be described by the definition used for massage; ‘a 
systematic and scientific manipulation of the soft tissues of the body with 
rhythmical pressure and stroking for the purpose of obtaining or maintaining 
health’ (Sritoomma et al 2014).   The therapeutic mechanism is thus described 
as ‘thought to relieve pain through several pathways, including increasing the 
pain threshold by releasing endorphins and closing the gate of pain at the spinal 
cord level.’ (Sritoomma et al 2014). 
 
This definition comes from a biomechanical perspective, the accuracy of which 
has been challenged in recent years.  Other authors however, have posited 
broader concepts, such as considering touch-based therapy as; an ‘informed 
‘desensitizer’ of the system’ (Zusman 2002), a tool to intervene in the  
interoceptive pathway (Courtois 2015); a neuroaffective process which can  
prepare patients to self regulate physiological activation (LaPierre 2003).  The 
resulting therapeutic benefits are now attributed to a broader ‘complex interplay 
between neurophysiological effects, placebo, patient expectation, and 
therapeutic alliance’ (Bialosky 2009).  Within Lederman’s (2015) ‘Process 
Approach’, MT is redefined as a ‘vehicle to deliver touch effects’ such as 
positive sense of sense and well-being’ items which are reportedly lacking in 
many FM patients (Schleicher 2005).  However there is no discussion in the 
literature regarding the length of time necessary for this interplay to reach a 




The aim of this systematic review was to assess if the current literature provides 
any evidence of a dose response relationship between MT and clinically 
important outcomes.   In order to assess the true efficacy of an intervention for 
FM, multi symptom outcomes need to be reviewed as recommended by the 
Outcome measures in Rheumatology Clinical Trials (OMERACT) FM working 
group.  Core symptom domains include; pain, sleep, emotional wellbeing and 
functional status (measured within Global measures of impact; functional 
impact and quality of life) (Mease 2009).   
 
A dose response relationship is described as a direct association between the 
level of exposure to an intervention and a desired effect or outcome.   
 
Any evidence regarding dose could inform further clinical trials in ensuring an 
optimal dose of MT is delivered, this would allow more accurate assessment of 




The protocol for this review was registered at www.prospero.com 
(No.CRD42018091401). 
 
Study eligibility criteria 
Eligibility criteria followed the PICO format. 
Population: defining the population as adults with a confirmed diagnosis based 
on the ARC criteria ensured a more homogenous group of participants across 
studies.  Intervention: presumed differences brought about by the mechanical 
properties of different MT styles were not the focus of this review, but rather 
the total dose of MT delivered to the participants, as a potentially 
biopsychosocial intervention.  Therefore the intervention type was kept broad to 
incorporate any soft tissue MT.  Soft tissue therapies delivered via machinery 
were excluded as the supposed psychological effects of human touch were 
absent.  C-tactile (CT) afferents play a role in affective touch, and have the 
potential to create neurophysiological and psychological change.  Only non-
glabrous skin contains CT afferents, therefore MT to glabrous skin only (such as 
reflexology) was excluded.  Control: recognising the limited numbers of studies 
investigating MT within FM, no limits were imposed on the control group 
criteria, to ensure sufficient articles for review.  Outcomes: it is important to 
examine multidimensional aspects of FM symptomology to truly investigate 
therapeutic efficacy, therefore OMERACT domains were used.   
 
Data sources 
A computerized systematic literature search was performed searching; AMED, 
BNI, CINAHL, Medline, EMBASE, PsycINFO, PubMed, and PEDro (inception 
through January 2018).  Only English texts were reviewed, no date restrictions 
were applied.  Reference lists from studies which met the inclusion criteria, and 
systematic reviews were manually reviewed.  
 
Electronic search strategy 
A broad systematic approach was conducted according to the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 
guidelines (Moher et al 2009).  Relevant literature was identified using the 
terms ‘fibromyalgia’ and ‘manual therapy’ with multiple synonyms (Table.1.).   
 
Table .1. Search Strategy 
Study selection 
All studies were scrutinized through their title and abstract. Potentially eligible 
texts were retrieved and evaluated; those selected were included for data 
extraction and synthesis. 
 
Data collection. 
Data were extracted using an adapted form (Bettany-Saltikov 2012). 
Due to missing data and the need for clarification on elements of the published  
data, attempts were made to contact authors of five studies.  Some authors were 





The first author (SS) assessed methodological quality for each study using the  
PEDro (Physiotherapy Evidence Database) scale, a number of studies were  
cross checked by the second author (CK) for inter-rater reliability. The  
PEDro scale is based on a Delphi list (Verhagen et al 1998) which uses 11  
items to identify the internal validity of a study, and to indicate when a study  
may have sufficient statistical information to make their results interpretable.  
 
PEDro scale scores range from one to ten points; with ≥ 6 representing a cut-off 
score for high quality studies (Maher et al 2003).  
 
Data analysis 
Studies were ordered according to the total dose of MT provided over the trial, 
from the smallest (least time) to the largest (most time), and grouped according 
to the outcome measured.  Where MT was used as the control, labelling of 
active and control was reversed in order to synthesise all MT study arms. 
Studies comparing two forms of MT where the dose of each MT differed, were 
reported twice, in order that each dose of MT was represented and analysed 
separately.   
 
Effect size (ES) was calculated as a measure of the effectiveness of treatment, 
Hedge’s g for between-group ES and Cohen’s d for within-group ES (Social 
Science Statistics, 2019).  
 
Where a study used more than one measure to examine the same outcome, the 
results of the multiple measures were standardised and averaged in order to 
provide one ES per outcome.  Effect sizes were standardised by reversal where 
necessary, in order that all positive figures demonstrated an improved outcome 
resulting from MT (e.g., a reduction in pain, or increase in function).   
 
To visualise any dose response pattern across all core domains, within-group  
 
ES versus MT dose were displayed on a scattergraph. For studies  
 
reporting a range of treatment times (Ekici et al 2009, Ekici et al 2017), the  
 




A narrative synthesis based on within, and between-group, comparisons was 
















A total of 4012 studies were identified through database searches and other  
resources; following removal of duplicates and exclusions, a total of 12 studies  
met the inclusion criteria (Fig.1).   
 




Table .3. summarises the characteristics of the included studies, along with a 
measure of methodological quality (PEDro scale). Sample sizes ranged from 12 
to 92 participants. Six studies stated all participants were female (Ekici et al 
2017, Castro-Sánchez et al 2014, Sunshine et al 1996, Liptan et al 2013, Lund et 
al 2016, Ekici  et al 2009), three studies included samples with over 94% female 
participants (Yuan et al 2013, Castro-Sánchez et al 2011a, Matarán-Peñarrocha 
et al 2011), one study had an approximately equal split of male and female 
participants (Castro-Sánchez et al 2014), and two studies did not state the 
gender of participants (Field et al 2002, Castro-Sánchez et al 2011c). 
 
Sixteen different clinical measures, and two different methods for assessing 
pain on palpation (PPT: Pressure Pain Thresholds, the minimum pressure 
required to induce a pain response & PTP: Painful Tender Point Count, number 
of painful regions on palpation) were used to assess the outcomes of interest.  
Four studies (Field et al 2002, Sunshine et al 1996, Lund et al 2016, Castro-
Sanchez et al 2011b) included both clinical outcome measures and biomarker 
measures.   
 
A range of MT interventions were used in the experimental groups. One study 
used MT as the control (Ekici et al 2017), and two studies tested two forms of 
MT against one another (Ekici et al 2009 & Liptan et al 2013).  Control 
interventions used active, placebo, and no treatment options. 
Methodological quality (PEDro scale) was classified as ‘high’ (scoring ≥ 6) for 
eleven of twelve studies. 
 
 
Table .2.  Summary of  Study Characteristics; Study Type, Participant Details, 'Manual 
Therapy' Intervention & Delivery Dose, Control/Comparator, Quality Score (PEDRo) 
 
  Table .2. (Continued) Summary of  Study Characteristics; Study Type, Participant Details, 
'Manual Therapy' Intervention & Delivery Dose, Control/Comparator , Quality Score 
(PEDRo) 
 
Synthesis of results 
 
Table.3. displays pre- and post-intervention scores, and within/between-group 
ES (Cohens d & Hedges g respectively).  Figures were taken from the literature 
or calculated where possible.  Studies were ordered according to the dose of MT 
delivered, from the smallest (least time) to the largest (most time), to look for 
evidence of a dose response.   
Table .3. Within and Between-Group Effect Sizes by Outcome Domains (Pain Outcomes) 
Table .3. Within and Between-Group Effect Sizes by Outcome Domains (Pain Outcomes - 
cont) 
Table .3. Within and Between-Group Effect Sizes by Outcome Domains (Mood Outcomes) 
Table.3. Within and Between-Group Effect Sizes by Outcome Domains (Sleep Outcomes) 
Table.3. Within and Between-Group Effect Sizes by Outcome Domains (Global Measure of 
Impact) 
Table 4 visualises the overall findings related to the question of evidencing a 
dose response relationship for all core domains.   
Table.4. Within-Group Effect Size versus Dose (MT Treatment Time)  
 
Pain outcomes 
Pain has always been the predominant target symptom for FM medicine, as it is 
the main source of suffering for the individual.  No evidence was found of a 
linear, dose response between MT and pain scores amongst FM participants.   
Large within-group ESs were found from treatment durations ranging from 
between one and four hours (Ekici et al 2017) up to 13 hours 20 mins (Yuan et 
al 2013).   
 
Yuan et al’s study (2013) recorded the greatest between-group ES (1.51), 
however, relative treatment efficacy cannot be guaranteed as the control group 
was an inactive wait list.  
 
Ekici et al (2009**) recorded the greatest within-group ES (2.4), for their 
MLDT treatment group (11 hours 15 min MT delivered).  This ES was almost 
double their comparative CTM group (delivering; 1 hour 15 mins – 7hours 30 
mins).  
 
Field et al (2002) and Yuan et al (2013) are the only two studies to present 
consistently large ESs for both within, and between-group results, suggesting a 
range of optimal dosing patterns, as being between five hours and 13 hours 20 
mins.   
 
Mood outcomes 
Low mood is a valuable therapeutic target for FM sufferers as a core domain of 
symptomatic treatment (Mease 2009).  Additionally, low mood can be a barrier 
to active engagement in behaviour change.  Addressing low mood therefore, 
supports the overall self-management approach to FM. The data presented here 
suggests an optimal dose of five hours MT, this dose being the only one to 
report a large within-group ES (0.92) ( Field et al 2002).  In this study however, 
the overall between-group ES was small, due to data from two measures (STAI, 
and POMS) favouring the control group.  The third measure used in this study 
(CES-D) recorded a statistically significant improvement for the massage group 
only; thereby creating an overall positive between-group ES.  With all three 
mood measures amalgamated, the CES-D score alone was responsible for the 
positive between-group ES.  In studies delivering more than five hours MT, 
mood measures reported a number of scores which did not reach clinical or 
statistical significance.  In contrast, the trials providing ≤ 5 hours, recorded 
moderate within-group ES and statistically significant change.   
 
Sleep outcomes 
There is a strong association between sleep disturbance and FM, whether the 
association is one of causation or consequence is unknown. Therefore improved 
sleep is an important therapeutic target for FM sufferers.  The results of this 
review did not identify a linear dose response between dose of MT and 
improvements to sleep.  The largest within-group ESs are seen by two studies 
conducted by the same authors, however, they delivered the shortest and second 
to longest duration of treatment within this cluster (Ekici et al 2017 = 1-4 hrs, & 
Ekici et al 2009** = 11hrs 15).  Different types of MT were delivered in these 
two studies, CTM and MLDT respectively.  These studies provided the highest 
intensity of treatments per week, three and five times per week respectively, 
comparative to other trials within the cluster. Between-group ESs only reached 
positive significance in Yuan et al’s (2013) study, however, relative treatment 
efficacy cannot be guaranteed as the control group was an inactive wait list.  
 
Global Measure of Impact outcomes 
Overall measure of disease impact is reflected by measures of multi-
dimensional Functional Status and Health related Quality of life (HRQOL).  
Gold standard approaches to treatment are therefore required to have a positive 
impact in overall measures of function, and HRQOL, to reduce the impact of 
FM.  The results of this review did not identify a linear dose response between 
dose of MT and improvements to FM impact.    
 
Within-group ESs were reported as large only in studies of  ≤13 hrs 20 (Yuan et 
al 2013).  The greatest ES was recorded by the MLDT group in the Ekici et al 
study (2009**) = (2.18).  Between-group results show moderate ESs, although 
some study results favour the control intervention. Of the three studies 
delivering 30 hours treatment or more, two studies; Castro-Sánchez et al 
(2011a) and Matarán-Peñarrocha et al (2011), report negative ES compared to 
the comparator.  However, both studies appear to have inconsistencies in the 







































This systematic review follows on from recent reviews (Li et al 2014, Yuan et 
al 2015, Terhorst et al 2011, Kalichman 2010, Terry et al 2011) looking at 
efficacy, and uniquely uses the literature to search for any evidence of a dose 
response relationship for optimal doses of MT.  This is an important enquiry as 
current clinical guidelines offer no support for the use of MT, in contrast to 
reported patient preference (Wahner-Roedler et al 2005).  Also, current 
approaches to FM fail to achieve significant and lasting clinical improvements 
(Thieme 2017) therefore further developments are necessary.  
 
This review has identified four important contributions to the study of the role 
of MT within the care of patients with FM, by looking at the question of dose. 
 
Firstly; this review has identified a paucity of contemporary research in this area 
of MT and FM.  The review did not identify a large evidence base, nor any new 
literature within the field since previous systematic reviews.  The criticism of 
MT as ‘unworthy and passive’ (Randell 1992), and therefore not consistent with 
the approach of active self management, has changed clinical practise as 
governed by guidelines.  Neglecting to continue with significant, contemporary 
research into this area, has prevented detailed assessment of MT’s potential 
clinical utility.  
Secondly; this review has suggested a lack of systematic dosing of MT as a 
potential consideration for the current lack of supportive evidence from recent 
systematic reviews and guidelines.  The range of treatment protocols used 
within the studies reviewed varied greatly.  Previous systematic reviews looking 
only for evidence of treatment efficacy have aggregated the effects from 
several studies; however the lack of precision of included studies due to 
different doses could distort the interpretation or ‘skew the results’ as suggested 
by Wallden (2015), thus masking the potential efficacy of correctly dosed MT. 
 
Of the twelve articles reviewed, five were produced by the same research team 
(Castro-Sánchez et al 2014, 2011a, 2011b, 2011c, Matarán-Peñarrocha et al 
2011), two were conducted by Ekici et al, and two were conducted by the Touch 
Research Institute (Field et al 2002 & Sunshine et al 1996).  Patterns seen 
within ESs were clustered according to authors, despite differing treatment 
doses used.  This could suggest other moderators, such as trial methodology and 
MT type, are also meaningful in the final results analysis. All studies were 
penalised on quality assessment (PEDro scale) due to lack of blinding of 
participants and therapists.  However, this is to be expected due to the nature of 
MT interventions, where neither participant nor therapist can be blinded.  
Allocation was not reported as concealed in six of the included studies; of these, 
three studies; Ekici et al 2009, Field et al 2002 and Yuan et al 2013, frequently 
report greater ESs than other trials under each outcome.  It is therefore feasible 
that this weakness in randomisation could have contributed to exaggerated 
results.  No other trends were seen correlating the quality of the study with ESs. 
 
Thirdly; MT has been shown to be effective through measures of ES.  This 
review did not provide sufficient data to identify, or refute the concept of a 
linear dose response relationship.  However the use of ES figures for four of the 
main clinically important domains, supports MT as an effective therapy.   
 
Within the cluster of studies measuring pain, five out of seven achieved large 
within-group ESs.  Of the two studies with only moderate ESs, Castro-Sánchez 
et al (2011c) provided a significantly larger dose of MT, thereby suggesting this 
extended protocol did not enhance outcomes.  Castro-Sánchez et al (2014) 
scored only a moderate ES, despite MT being compared to no treatment. 
However this trial differed from every other trial in the review as fifty percent 
of its participants were male; a tentative suggestion could be made that gender 
differences influenced the study results, and should therefore be considered in 
deciding on optimal dose and treatment expectations.   
 
Effect sizes for measures of mood present a more linear response.  Increasing 
ESs are seen as treatment doses rise from one hour to five hours, and then drop 
to moderate ES, with the longest protocol of 13 hours 20 mins. However, in 
their discussion, Lund et al (2016), suggest their results identified individual 
responses to treatment confirmed by measure of Relative Rank Variance (RV).  
Different subgroups of people, with different affect symptoms were thought to 
respond differently.  This lends further support to the concept identified through 
pain measure analysis, that individual variations must be considered in planning 
doses for optimal outcomes. 
 
Effect sizes for measures of sleep do not present a consistent dose response 
pattern, however the highest ES was detected with Ekici et al’s study (2009**).  
This study delivered MT five times per week, and both MT treatment arms 
achieved ESs greater than one.  The only other study to achieve an ES of greater 
than one was Ekici et al (2017) which delivered MT three times per week.  All 
other studies did not reach an ES of one, and had less frequent MT sessions per 
week.  A tentative suggestion could therefore be made; if the focus of treatment 
is to improve sleep, the frequency parameter may be critical, thus increasing the 
frequency may lead to improved outcomes. 
 
Looking at the domain of overall FM impact, this review has identified a trend 
for the lesser dosage studies (≤ 13 hours 20 mins) achieving larger ESs.  As was 
found with the other clinical domains, the more intense dosage patterns 
provided the greater ESs, with the optimal dose being 45 minutes, five times per 
week for three weeks (Ekici et al 2009**).  As the dose becomes extended over 
a longer period, 20-25 weeks, for the final three studies in this cluster, ES drops.  
These studies provided longer individual sessions, and a greater total amount of 
MT compared with the more successful studies, however they failed to increase 
outcomes. They were delivered once or twice weekly which mirrors two of the 
studies found in the highly effective cluster, and therefore this weekly frequency 
cannot be claimed to be suboptimal.  Myofascial Release (MFR) and Cranio 
Sacral Therapy (CST) were the interventions delivered in these, less effective 
trials, therefore it could be suggested that the decrease in efficacy relates to the 
chosen intervention rather than the dosage pattern.  With the exceptions of Ekici 
et al (2009) and Liptan et al (2013), no other trials have compared different 
forms of MT, and therefore this suggestion cannot be further explored within 
the current literature.  The trends seen within this review identify Ekici et al 
(2009**) as generating higher than average ESs across the domains, thereby 
suggesting MLDTs comparative effectiveness against other MT interventions. 
 
Considering the more immediate and short term results from MT across pain, 
sleep, and mood, there would be an expected improvement in quality of life as 
an individual’s perspective becomes more positive.  This outcome would be 
best captured through qualitative studies, which was outside the scope of this 
review.  This review suggests the biopsychosocial integration of MTs effects 
leading to a decreased impact of disease.  However, as a stand-alone 
intervention, the impact starts to reduce over time.  Gold standard approaches 
for FM are currently multidisciplinary, due to the multidimensional nature of 
the illness process.  Therefore the role for correctly dosed MT interventions 
may be to prepare appropriate patients bio-pyscho-socially, as part of an 
integrated approach, and should not be assessed as single intervention, for long 
term change. 
 
By combining the results and discussion points from each domain, it is possible 
to tentatively suggest a baseline dose of 45 minutes MT, three to five times per 
week, for three to five weeks, totalling 11.15 hours, as a generic protocol for 
treatment planning with further refinement of a personalised dose (Díaz-
Rodríguez et al 2016), dependant on gender and affect.  Finally, outcomes 
oriented dose parameters, either as a single intervention for a single domain, or 
as an integrated part of a multidisciplinary self management program, may need 
to be set. This protocol moves beyond the earlier recommendation by Li et al’s 
(2014) meta analysis concluding that MT of ≥ 5 weeks achieved beneficial 
effects for FM patients.  
This recommended protocol raises challenges for health care provision, such as 
financial and staffing implications which would need to be considered.  In a 
climate where multidisciplinary staffing is already reported as insufficient in 
many pain services throughout the UK (Price et al 2018); increased levels of 
staffing and potentially an extended skill mix would be required.  Increased 
patient contact time would require additional funding, at a time when the 
sustainability of healthcare is already under scrutiny.  Currently, self-
management programs are able to provide cost efficiencies due to large 
numbers of patients being seen simultaneously.  Costs would therefore be seen 
to increase in the short term with the addition of this protocol.  However, these 
costs could be met by longer term decreases in healthcare utilisation amongst 
FM patients, as a result of improved clinical outcomes. 
 
Whilst the evidence suggests potential predicators for good responders to 
treatment; these identifiers would need to be established in order to work with 
low ‘numbers needed to treat’ (NNT), to guarantee cost, and clinical 
effectiveness.   
 
The biggest implication of all could be seen by some, as a move back towards 
medicalisation of FM, and the ‘passive recipient of medicine’ model of 
healthcare.  The NHS Five Year Forward View (2014) puts forwards the issue 
of sustainability for the NHS.  Long term conditions, rather than illnesses 
susceptible to a ‘one-off cure’, are suggested as areas where prevention, and 
supported self-management, should be the approach of choice.   
 
Identifying when and where a treatment intervention would fit within the over 
arching self-management approach, would require clear rationales, patient 
specific guidelines, and outcome measures; to ensure efficacy, and cost 
effectiveness.    
 
The fourth contribution made by this review is to describe the reasons used for 
dose selection, and the consideration for dosage parameters that are found in the 
current literature.  
The reviewed articles each described the mechanical effects proposed to be the 
active ingredient within MT.  Central effects; cortisol reduction, immune and 
neuroendocrine enhancement, increased serotonin, psychological shifts, 
stimulation of endogenous opioids, and peripheral effects; increased circulation, 
decreased muscle tension, increased oxygenation of tissues, reduction of fibrous 
adhesions, were proposed.  Only three studies attempted a discussion related to 
the rationale for the dosage of MT used. Castro-Sánchez et al (2011c) described 
testing an increased dose as a development on previously conducted research.  
In their discussion they stated that by increasing from once, to twice-weekly 
treatments, there were improvements in pain, sensory and affective dimensions.  
Ekici et al (2009) described how each dose/session of connective tissue massage 
was determined by patient experience, and observed vascular skin changes 
during the treatment.  This form of person centred, subjective approach to dose 
did not provide greater results against the comparator treatment, and therefore 
did not support tailoring dose in this way.  Liptan et al (2012) described testing 
a ‘low dose’ based on the therapist’s clinical experience, and to enhance patient 
acceptability; all studies showed high levels of patient acceptability for MT 
through low drop out figures, and therefore this rationale for a low dose appears 
unsupported.  The limited explanation of the rationale behind MT dosages, 
indicates that this concept is not routinely considered when trialling MT 
interventions.  
Moyer et al’s (2004) meta-analysis for massage therapy research, comments on 
the limited evidence for ‘body-as-machine’ rationales (pain gate stimulation, 
circulatory effects) for the application of MT, and suggested the notion of MT 
as a comparable intervention to psychotherapy.  Using a somatic 
psychotherapeutic paradigm for understanding the therapeutic action of MT, led 
to the suggestion that perspectives gained from psychotherapeutic research 
should be applied to future MT trials.  Psychotherapy literature also lacks a 
clear protocol of optimal dose, however there is a general consensus that 13-18 
sessions are required to help 50% of patients (Hansen et al 2006).  
 
Kalichman, in his 2010 review, recommended future studies should not only  
look at physiological and psychological effects but also the evidence for how  
these effects come about. Four of the included studies (Field et al 2002,  
Sunshine et al 1996, Lund et al 2006, Castro-Sánchez  et al 2011b) included  
both clinical outcome measures and physiological mechanisms measures.  
Insufficient numbers of studies analysed the same biomarkers, therefore the  
question of optimal dose could not be explored through physiological markers 
within this review. 
 
Other literature has commented on possible optimal doses when considering 
MT;  Brattberg (1999) stated the analgesic effect of Connective Tissue Massage 
(CTM) appeared gradually with the first 15 treatments.  Of those successful 
studies within the pain domain, the only one (Castro-Sánchez et al 2014) to drop 
below a large ES, delivered only five treatments, the others in the cluster 
delivered 10-16, consistent with Brattberg’s suggestion.  Sailer et al (2016) 
showed functional connectivity of brain regions changed throughout a 40 
minute session of slow stroking, with increasing activation in brain reward 
centres during the first 20 minutes. These numbers reflect the timings found in 
the most effective trials within this review from Ekici et al (2017) being the 
shortest only just reaching 20 minutes, and Yuan et al (2013) at 50 minutes. 
This could indicate changes in functional brain connectivity, as an important 
component of therapeutic change, and therefore a longer dose of treatment 
would be unnecessary.   Rapaport et al (2012) showed that in healthy 
individuals the dosage and frequency of light touch, and in particular massage, 
increased its efficacy, with twice a week treatments having a far longer lasting 
and more effective biologic activity than once weekly.  Kalichman (2010) also 
noted in his review that all successful studies used a MT intervention once to 
twice per week.  This review added to the evidence of increased frequency 
creating improved outcomes.  The two studies showing the greatest ESs across 
domains provided the most frequent treatments per week; Ekici et al (2009 & 
2017) providing five and three sessions per week respectively.   
Moving away from the biomechanical explanatory model for MT, research has 
provided the notion of MT as an ‘interoceptive generator’ driving 
neuroaffective processes of physiological self regulation (Courtois 2015, 
Calsius et al 2016, and LaPierre 2003).  This perspective positions MT as an 
appropriate therapeutic tool for the proposed lack of neurodevelopmental self 
soothing systems, thought to be a risk factor for development of FM (Low & 
Schweinhardt 2011).  In order to assess outcomes or change along these lines of 
enquiry, qualitative data would provide a more valuable resource.  No 
qualitative or mixed methods studies were included in the review.   Dupuis 
(2015) however, reported that following one session of fasciatherapy, FM 
patients stated their symptom relief was ‘very important in improving the 
relationship they had with their body, and reassessing their lifestyle’.  Mooney 
(2015), reported changes in attitude and awareness that enabled FM patients to 
feel less helpless and more capable of choosing optimal personal treatment 
plans, following an established protocol of Medical Massage (12 sessions of 40-
60 minutes).   
 
These qualitative changes in patients’ perceptions and readiness for change 
could indicate a powerful therapeutic outcome of MT, but again, the question of 
dose was not discussed in these studies.  A change in perception, body 
awareness, and readiness for change, suggests MT could be a useful adjunct to 
multi-modal approaches, however no studies were found in this review 
exploring MT as an adjunct to usual care.   Celenay et al (2017) did demonstrate 
a MT intervention of 5-20 minutes twice per week for six weeks, as an adjunct 
to exercise therapy.  Their results showed significantly increased beneficial 
















Combining of different styles of MT, and having a wide inclusion for control  
groups is a limitation in this study.  Tighter restrictions would have created  
more focus on the dose being the only variable; however tighter restrictions  
of the original search would have resulted in insufficient numbers of articles to  
analyse.  The response to MT is likely to occur on many biopsychosocial levels,  
and therefore the variety of styles of intervention may be of lesser importance  
when answering a question of dose. 
 
Due to heterogeneity of outcomes used, and lack of raw data, data analysis was  
not possible for all the included studies, therefore limiting the data available for  








This review did not identify a linear dose response relationship using the current 
literature, however it presents the current evidence base in such a way as to 
highlight the moderate and large ESs associated with a variety of MTs.  It 
provides a tentative formulae for MT delivery; 45 minutes, three to five times 
per week, lasting three to five weeks, and an overall dose of approximately 
11.15 hrs; with the clear mandate to further define a stratified approach to MT 
use, under certain conditions and for certain patients. 
 
An unintentional result of this review was to identify a paradigm shift in the 
explanatory model for MT away from biomechanical, and towards 
neuroaffective physio-psychologic (Field 2014).  This calls for a more holistic 
way of assessing effect, thereby indicating the need for mixed methods research 
approach. 
 
Viewing MT from this new perspective, could redefine MT as an intervention 
which is not in conflict with the self-management approach, but could be used 
as an adjunct.  By facilitating a physiopsychological change, FM patients may 
be enabled to participate more fully in active approaches to self-management.  
MT would therefore need to be assessed as an adjunct to normal care, rather 
than as a stand-alone intervention.   
By analysing the data in this way, the overall suggestion is one of treatment 
utility under many clinical outcomes, with the need to refine dosing parameters 
dependant on individual patient characteristics such as gender and affect, and 
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Chronic multi-symptom* disorder Manual manipulation
Chronic multi system* disorder Light touch
Central sensitivity syndrome Bowen
Myofascial pain Rolfing
Somataform disorder Connective tissue massage (CTM)
Functional somatic syndrome Network spinal analysis (NSA)
Widespread pain disorder Osteopathy










Table 3         Within and Between-Group Effect Sizes
Baseline: mean 
(SD)





Final: mean  
(SD)           
N
PPT R 1.51 (0.46) 2.30 (0.76) 1.43 (0.30) 2.75 (0.52)
PPT L 1.64 (0.55) 2.47 (0.90) 1.53 (0.34) 3.03 (0.61)
VAS 6.62 (2.45) 2.53 (2.16) 8.75 (0.91) 2.15 (0.90)
PPT R 1.64 (0.56) 2.41 (0.74) 1.68 (0.57) 2.82 (0.72)
PPT L 1.91 (0.94) 2.66 (1.04) 1.66 (0.47) 2.95 (0.78)
VAS 6.52 (2.29) 2.59 (2.05) 6.98 (1.91) 1.49 (1.19)
MPQ PPI 2.25 1.7 2.4 2.35
MPQ PRI     40.05 33.8 39.75 39.55
VAS 7.7 6.5 8 7.5
TPC (20) 15.8 - 15.9 -
PPT (kPa)          343.21 440.92 385.7 387.8
TPC (18) 15.4 (1.7) 10.5 (6.1) 16.1 (2.2) 14.6 (4)
VAS 6.0 (3.2) 3.7  (2.9) 7.7 (1.6) 6.3 (3)
VAS 8.6 5.3 8.15 7.25
PPT (kg) 3.4 4.5 2.85 3.35
Lund et al, 2006                                      NHP - - 10 - - 6 - -
No raw data available. Less indications of pain post treatment reported by; 
1/10 participants in the MT group and 3/6 in the relaxation group. One month 
after intervention, 4/10 in the MT group & 2/6 in relaxation group, report less 
pain.
PPT R 1.68 (0.57) 2.82 (0.72) 1.64 (0.56) 2.41 (0.74)
PPT L 1.66 (0.47) 2.95 (0.78) 1.91 (0.94) 2.66 ( 1.04)
VAS 6.98 (1.91) 1.49 (1.19) 6.52 (2.29) 2.59 (2.05)
No raw data available. Aicken separation test indicated further research is 
needed to compare MFR and swedish massage, both treatments were well 
tolerated, and effective, with no significant difference between them.  The 
study suggests that MFR may result in greater reductions in pain.  Parrallel 
design attempted to reduce confounding influence of placebo.  NMQ; scores 
improved in both groups.
Ekici et al,                        
2009 **                                      
25 25 2.4 0.51
Both treatments led to significant improvements  (P < .05) in pain.  The 
decrease in VAS resulting from MLDT  indicates high clinical significance.   
Pain Outcomes
Ekici et al,                                         
2017                                      
21 15 1.38 -0.53
VAS; Both groups experienced significant improvements (P = > .05), both 
groups also showed improvements in PPT.
TPC and VAS reduced significantly (P < .005 and P < .001 respectively), with no 
significant reduction in control group.
Sunshine et al,                            
1996                                                                             
10 10 - -
No SD data available, therefore effect size could not be calculated.  The MT 
group alone reported significant improvements in self reported pain, and pain 
threshold.  Two control groups were compared, active electrotherapy and 
sham . Results from both groups were combined, and mean values were used 
for the purpose of analysis.
Field et al,                                                       
2002                                                      
10 10
Liptan et al,                                 
2012                                      
modified NMQ - - 6 - - 6 - -
0.92 0.84
Castro-Sánchez 
et al, 2014                                      
45 44 0.72 -
MT was effective in achieving statistically significant improvements in; pain 
intensity, TPC, PPT.  Sex differences were observed, women responded more 
than men in impact of FM and pain, men showed a greater decrease in 
depression  and PPT than women, similar improvements were seen in sleep 
and tender point count.                                                                                                                        




---------------- MT GROUP ---------------- ------------ CONTROL GROUP ------------ Within group 







Both treatments led to significant improvements  (P < .05) in pain, CTM 
improvements were smaller and with a greater SD than for MLDT.  No baseline 
statistical difference in pain measures were reported between groups.
Ekici et al, 2009*
Table
Table 3         Within and Between-Group Effect Sizes
Baseline: mean 
(SD)





Final: mean  
(SD)           
N
VAS 7.2 (2.3) 5.1 (2.5) 6.4 (1.1) 7.1 (1.8)
MT group: 40.6% change in VAS pre-post;  clinically significant relative to 
control group
PPT - (kg) 0.8 (0.4) 1.2  (0.6) 0.8 (0.4) 0.6 (0.4)
MT group: 76.4% change in PPT pre-post;  clinically significant relative to 
control group
VAS                    - - - -
No raw data available.  MT group: significant improvement (P < 0.43) in pain 
versus baseline & control group.  Results illustrations suggest mean decrease 
of just over 10mm on VAS post intervention.
PTP 14.4 7.9 18.4 18.5
No SD available.  Reduced numbers of patients reporting painful tender points 
at all 18 sites in MT group;  statistically significant reduction in  8/18 tender 
points.  No change in control group.
Castro-Sánchez 
et al, 2011b                                          
PTP 36.1 27.9 46 35.6 35.4 46 - -
No SD available.  Significant decrease in number of patients with tender points 
at 13/18 tender point sites versus baseline, and control group. 
MPQ VAS 9.13 (0.8) 7.98 (1.03) 8.9 (1.3) 8.87 (1.01) Significant improvement in mean pain score versus baseline (F=6.19, P<0.026).  
MPQ - sensory 19.3 (9.2) 16.5 (8.6) 19.9 (10.6) 20.3 (6.5) Significant improvement in mean score versus baseline (F=3.21, P<0.041).
MPQ - 
affective 
5.6 (3.4) 4.2 (3.4) 4.9 (4.2) 5.3 (4.1) Significant improvement in mean score versus baseline (F=5.29, P <0.031).
MPQ - 
evaluative 
24.9 (12.6) 20.6 (6.3) 25.3 (10.7) 25.9 (5.3) Signifcant improvement in mean score versus baseline (F=5.44, P <0.032).
PTP 32.4 24.8 32.3 32.5
Significant decrease in number of tender points versus baseline in 7 of 18 
tender points.  No change in control group
Matarán-
Peñarrocha    et 
al, 2011                        
VAS 9.13 8.18 43 8.9 8.88 41 - -
No SD available.  Significant improvement versus baseline (P <.035), and versus 





Pain Outcomes  (Continued)
Castro-Sánchez 
et al, 2011a                                   




---------------- MT GROUP ---------------- ------------ CONTROL GROUP ------------ Within group 




45 41 0.6 0.64
Yuan et al, 2013                                                      17 17 0.83 1.51
Table
Table 3         Within and Between-Group Effect Sizes
Baseline: mean 
(SD)





Final: mean  
(SD)           
N
STAI - state 48.33 (12.56) 41.81 (12.50) 47.73 (10.67) 32.33 (7.25)
STAI - Trait 50.71 (10.63) 46.05 (7.55) 55.07 (10.63) 45.33 (7.95)
Castro-Sánchez 
et al, 2014    
CES-D 23.7 (8.3) 18.8 45 25.9 (6.9) 26.15 44 0.69 -
2 X 2 mixed ANCOVA indicates significant group X time interactions for mood P 
= < 0.001 with those in the MT group achieving better outcomes than the 
control.  Effect size taken from article, pressumed to be within group effect 
size, unable to check calculations as no SD available.
CES-D 18.0 (9.2) 12.3 (9.5) 17.7 (8.7) 17.1 (5.3)
STAI 43.7 (9.5) 31.1 (11.2) 41.9 (8.5) 29.2 (6.7)
POMS 10.0 (9.9) 2.8 (4.5) 11.0 (9.2) 1.8 (3.2)
STAI                45.4 34.1 47.2 35.3
POMS 17.3 12 17.25 12.75
CES -D 31.9 26.8 31.8 28.6
Lund et al, 2006 
CRPS-A                    
NHP
- - - - - -
No raw data. Non-zero RP value indicates there was a group wide systemic post 
intervention improvement in CRPS dimensions following massage (P = 0.02), 
the group change was reduced one month post treatment, and individual 
variation was increased.  NHP showed reduced emotional reactions in 6/10 
massage, 3/6 relaxation group, 1month after intervention 6/10 massage, 1/6 
control group reported reduced reactions.
STAI - S 53.9 (8.4) 48 (10) 55.5 (11.2) 52.1 (11.3)
STAI-S: 4.62% decrease pre-post, not clinically or statistically different vs 
control group
STAI - T 57.9 (9.4) 53.1 (9.1) 52.9 (11.6) 55.5 (12)
STAI-T: 13.22% decrease pre-post not clincally significant, but statistically 
different vs control group.
STAI - - - - STAI: No mean/SD data.  Significant improvement in trait anxiety  reported (p = 
< .041) vs baseline & control .  No change in state anxiety.
BDI - - - - BDI: No mean/SD data.  No change reported in either group vs baseline.
BDI 2.52 2.08 2.5 2.52 No sig diff between groups or versus baseline
STAI - state 23.32 20.53 22.28 24.43 P  < .029 sig difference in MT versus baseline
STAI- trait 26.88 25 26.15 26.7
P < .042 sig difference in MT versus baseline . Significant difference between 
group  P  < .045.
STAI and POMS were measured before and after interventions on the first and 
last days; immediate and significant improvements were reported in both 
measures, both time points for both groups, favouring relaxation slightly.  Only 








Sunshine et al,                            
1996 
10 10 - -
Yuan et al, 2013 17 17 0.58 0.31
Narrative Comment 
Mood Outcomes
Ekici et al,                                         
2017    
21 15 0.51 -0.49
Both groups experienced improvement in pre-post scores for State and Trait 





---------------- MT GROUP ---------------- ------------ CONTROL GROUP ------------ Within group 





STAI and POMS were measured before and after interventions on the first and 
last days; immediate and significant improvements were reported in both 
measures, at both time points for the experimental group.   The control groups 
experienced smaller improvements and in the sham TENS some outcomes 
worsenend. The improvements in CES-D outcomes did not reach significance. 
No SD data available, therefore effect size could not be calculated.
Field T et al,                                                        
2002  
10 10 0.92 0.05
Table
Table 3  (continued)         Within and Between-Group Effect Sizes
Baseline: mean 
(SD)





Final: mean  
(SD)           
N
Ekici et al, 2017 NHP - S 28.24 (27.49) 5.22 (8.80) 21 37.44 (30.92) 6.95 (8.01) 15 1.13 0.2
Both groups reported an improvement (P = > .05) = small between group Effect 
size
Ekici et al,                        
2009*     
NHP item 27.72 (30.72) 4.38 (8.26) 25 35.89 (29.82) 4.44 (8.66) 25 1.04 0.01
Both groups experienced significant (P < .05) improvements. Between group 
final Effect size shows little difference, favouring CTM.   Variance in baseline 
figures, shows a greater reduction in 2nd (MLDT) group .
Castro-Sánchez  
et al, 2014    
PSQI (0-21) 16.9 (3.3) 14.55 45 16.9 (4.2) 16.6 44 0.72 -
No SD was available, effect sizes were reported in the study.                              2 
X 2 mixed ANCOVA indicates significant group X time interactions for sleep (P = 
< 0.001) with those in the MT group achieving better outcomes than the 
control.  No significant interaction of gender on outcomes.
sleep hours 5.8 (1.1) 6.4  (1.1) 5.6 (1.3) 6.2 (.8)
sleep 
movements
101.3 (57.5) 83.3 (52.8) 86.1 (45.5) 74.6 (24.8)
Sunshine et al,                            
1996 





6.1 3.4 10 4.65 4.1 10 - -
The massage group only reported a significant reduction (P = 0.005) in nights of 
sleep disturbance. 
Ekici et al,                        
2009**     
NHP item 35.89 (29.82) 4.44 (8.66) 25 27.72 (30.72) 4.38 (8.26) 25 1.43 -0.01
Both groups experienced significant (P < .05) improvements. Between group 
final Effect size shows little difference, with a negative ES with MLDT as Exp 
group.  Variance in baseline figures, shows a greater reduction in 1st (MLDT) 
group .
Yuan S et al, 
2013
PSQI (0-21) 12.0 (4.0) 8.1 (5.2) 17 11.9 (4.7) 12.1 (4.3) 17 0.84 0.84




PSQI - - - - - -
No means or SD.  MT group showed significant improvement vs baseline in 
sleep latency (p = <.041) and sleep duration (p = <.039), no other items 




PSQI (0-21) - - 43 - - 41 - -
No means or SD.  MT group had significant improvement in total score P < 
.043, with significant difference in items for sleep duration and sleep 






Field et al,                                                        
2002  
10 10 0.44 0
The experimental group recorded a significant reduction in recorded 
movements and increased hours of sleep versus baseline.  The final sleep 
movements recorded for the experimental group remain higher than the 





---------------- MT GROUP ---------------- ------------ CONTROL GROUP ------------ Within group 
(MT)  Effect 
Size (d) 
Table
Table 3  (continued)         Within and Between-Group Effect Sizes
Baseline: mean 
(SD)





Final: mean  
(SD)           
N
NHP 212.73 (124.5) 80.79 (64.73) 21 294.25 (90.21) 69.03 (38.34) 15
FIQ 50.20 (22.46) 28.68 (14.22) 21 55.12 (10.07) 22.12 (4.58) 15
NHP 201.22 (129.16) 76.89 (63.21) 198.95 (96.63) 52.93 (31.61)
FIQ 49.51 (20.99) 28.55 (13.46) 47.81 (15.59) 18.88 (8.30)
Castro-Sánchez 
et al, 2014    
FIQ                        66.7 56.65 45 67.6 66.75 44 0.87 -
No SD available; effect size data taken from article.  MT had a significant effect on 
impact  post treatment.  Women had greater ES on FIQ than men   (W = 1.09, M = 
0.64).
Liptan et al,                                 
2012  
FIQ-R - - - - - -
Aickin separation test indicted change score trended in the hypothesised 
direction (favoured MFR over SM), MFR group (mean = 10.14, SD = 16.2) SM 
group (mean = 0.33, SD = 4.93). Between group difference was not significant. 
5/8 subjects  in MFR group reported clinically significant improvement (1/8 of SM 
group reached significance), 3/8  = >30% reduction in score (14% reduction is 
rated as clinically significant).
NHP 198.95 (96.63) 52.93 (31.61) 201.22 (129.16) 76.89 (63.21)
FIQ 47.81 (15.59) 18.88  (8.30) 49.51 (20.99) 28.55 (13.46)
Yuan et al, 2013 FIQ 66.7 (18.8) 48.2 (20.4) 17 65.2 (16.1) 61.4 (17.8) 17 0.94 0.69 MT group: 22.30% change pre-post;  clinically significant relative to control 
SF-36 physical 
function
5.23 (5.36) 46.72 (6.71) 50.24 (8.47) 51.03 (8.24)
SF-36 physical 
role
25.97 (7.32) 22.91 (7.15) 26.36 (6.25) 26.32 (6.29)
SF-36 body 
pain
76.56 (6.31) 73.93 (8.21) 78.93 (11.43) 77.54 (11.63)
SF-36 general 
health
67.82 (5.21) 65.20 (5.43) 68.78 (7.22) 69.85 (6.24)
SF-36 vitality 60.85 (6.41) 63.53(8.17) 59.42 (5.32) 59.99 (9.41)
SF-36 social 
function
64.03 (8.03) 59.55 (4.22) 64.43 (13.22) 64.03 (10.15)
SF-36 emot' 
role
48.98 (8.13) 46.42 (11.32) 46.55 (7.32) 47.74 (9.26)
SF-36 mental 
health





64.95 (18.2) 56.10 (17.3) 45 63.94 (16.4) 65.85 (18.5) 41 0.5 0.54
The FIQ total score showed significant improvement vs baseline in the MT group; 




49.43 (6.90) 45.90 (5.87) 51.90 (9.92) 50.53 (9.12)
SF-36 physical 
role
25.17 (6.88) 22.10 (6.84) 25.86 (7.35) 25.8 (6.98)
SF-36 body 
pain
75.76 (7.2) 73.12 (6.08) 78.43 (12.75) 78 (13.07)
SF-36 general 
health
67.02 (4.25) 64.40 (4.65) 68.28 (6.84) 68.35 (6.39)
SF-36 vitality 60.05 (5.23) 62.73 (5.27) 58.90 (6.27) 59.48 (7.73)
SF-36 social 
function
63.23 (7.12) 58.75 (6.74) 63.93 (12.41) 63.50 (11.57)
SF-36 emot' 
role
49.18 (7.65) 45.60 (7.85) 46.35 (5.69) 47.23 (5.66)
SF-36 mental 
health
76.65 (11.23) 77.48 (8.73) 80.60 (9.66) 81.15 (10.42)
1.21 -0.67
2.18 0.67
The results section describes significant improvements for the MT group in; 
physical function, (p < .024), physical role (p <.020), body pain (p < .043), general 
health (p < .039), vitality (p < .041), and social function (p < .029).  However, 
Results Table 2 shows lower post intervention scores, (lower scores on SF-36 
indicate decreased quality of life and more disability).  These items also recorded 
significant differences between the 2 groups, with the control group not 




30 29 0.63 -0.36
The results section reports significant improvement versus baseline in; physical 
function p = < .007, physical role p= < .039, body pain p = < .043, and social 
function p = <.048 , and no changes within control group.  However, results table 
4 shows reduced scores for the MT group (lower scores reflect decreased quality 
of life and more disability).                                                                                                                                                                                                  
Figures given in the results section state the baseline score for physical function 
in the experimental group was 5.23, this number appears very different from the 
other results figures and may be an error; calculated Effect Size figures may 
therefore be unreliable. 
Matarán-
Peñarrocha et al, 
2011
43 41 -0.4 -0.37
MLDT led to statistically significant improvements in FIQ (p = 0.010) versus CTM.
Ekici et al,                        
2009**     
25 25
Narrative Comment 
Global Measure of  Impact
Ekici et al,                                         
2017    
1.39 -0.4
Significant reductions were seen in both groups on both measures (FIQ: P  = 
0.001).  Within each measure, sub items favoured Pilates or CTM. FIQ  items: 
'work missed' and 'physical impairment', were the only improvements to not 




---------------- MT GROUP ---------------- ------------ CONTROL GROUP ------------ Within group 





Ekici et al,                        
2009*     































   









Table .2.  Summary of  Study Characteristics; Study Type, Participant Details, 'Manual Therapy' Intervention & 
Delivery Dose, Control/Comparator, Quality Score (PEDRo) 
 






Participant Detail; Sample 
Size, Age, Gender
Interventions; Duration, Number 
and Frequency of Sessions, Total 




Ekici et al, 2017                                                                                                                                                                       RCT
Sample size: EG (PE) = 21, CG 
(CTM) = 22 .                                              
Age: mean 37 yrs  (SD 7yrs).           
Gender; all female
Pilates versus CTM.                                                              
Pilates; 1 hour class 3 x/week for 4 
weeks                                              
CTM; 5-20 mins 3 x/week for 4 
weeks.                                                   
Total MT dose: 1-4 hours
Pain: PPT algometry and VAS.                                                         
Sleep: NHP item                                                                         
Mood: STAI.                                                                                        
GMI: NHP, FIQ.                                                                       
Other: nil                       
9
Ekici et al, 
2009*                 
(First entry - 
CTM data used 
as experimental 
group)                                                                                       
RCT
Sample size: Exp = 25, Control 
= 25                                       
Age range: >25 yrs, average 
37.9 yrs.                         
Gender: all female.                           
CTM versus MLDT                  
CTM; 5min- 20 min session 5 x/week 
for  3 weeks                                                                                 
Total dose CTM: 1hr 15 - 7hrs 
30                                   
Pain: PPT algometry and VAS                                                                       
Sleep: items within NHP                                                                                 
Mood: nil                                                              




et al, 2014                                                                                                                                 
RCT
Sample size: EG = 45,  CG = 44         
Age range: 18-70 yrs                      
Gender: 54% female, 46% male
Manual therapy versus no treatment               
45 minute session 1 x/week, for 5 
weeks                                          
Total MT dose: 3 hrs 45
Pain: PPT algometry – mean of three trials, 
over 20 tender points.   McGill Pain 
Questionnaire: PRI, and PPI, VAS + Body 
chart.                                                                    
Sleep: PSQI                                                                                           
Mood: CES-D                                                                            
GMI: FIQ                                                                                   
Other: nil
9
Field et al, 2002                                                                                                                                                                                      RCT
Sample size: 20                                                                           
Age range: average 50.9 yrs
Gender: ?
Massage versus relaxation                            
Massage: 30 mins 2 x/week for 5 
weeks                                       
Relaxation: 30 mins 2 x/week for 5 
weeks                                             
Total MT dose: 5 hrs
Pain; VAS, algometry over 18 sites                                                   
Sleep; sleep log, timex motion recorder 
overnight                                            
Mood; STAI, POMS, CES-D                                                                                        
GMI: nil                                                                                    
Other; saliva samples for substance P
6
Sunshine et al, 
1996                                                                                                                
RCT
Sample size: 30                                                                  
Age range: 18-80 yrs                                                                  
Gender: all female
Massage versus TENS and sham 
TENS                                              
Massage: 30mins x 2/week for  5 
weeks                                          
Controls: 30 mins x 2/week for 5 
weeks                                                                       
Total MT dose: 5 hrs
Pain: algometry on 18 tender points                                       
Sleep; interview                                                                                     
Mood: STAI,  POMS, CES-D                                               
GMI: interview on daily functioning.                                               
Other:salivary cortisol.                                             
5
Liptan et al, 
2013                                                                                                     
parallel study non 
randomised
Sample size: 12                                                            
Age range: 21-50 yrs                                       
Gender: all female
MFR versus SM                                                                    
MFR: 90 mins session 1 x/week for 4 
weeks                                           
SM: 90 mins session 1 x/week for 4 
weeks                                              
Total MT dose: 6 hrs
Pain; localised pain measure – modified 
NMQ                                                                       
Sleep: nil                                                                                  
Mood: nil                                                                                     
GMI: FIQ R                                                                                     
Other: nil
6
Lund et al, 2016                                                                                                                RCT
Sample size: EG = 10, CG = 9                                                           
Age: mean = 50.7yrs (SD 9.7 
yrs)                                          
Gender all female
Massage versus relaxation                                                     
30 min session 2 x/week for 6 weeks                                                   
Total MT dose: 6 hrs
Pain: Swedish version of NHP                                                                                                      
Sleep: nil                                                                                  
Mood: CRPS - A, NHP                                                                                   
GMI: nil                                                                                    






Table .2. (Continued) Summary of  Study Characteristics; Study Type, Participant Details, 'Manual Therapy' 
Intervention & Delivery Dose, Control/Comparator , Quality Score (PEDRo) 
 






Participant Detail; Sample 
Size, Age, Gender
Interventions; Duration, Number 
and Frequency of Sessions, Total 




Ekici et al, 
2009**  




group)                                                                                                      
as above as above
MLDT versus CTM                
MLDT; 45 min session 5 x/week for 
3 weeks.                                                                                                




Yuan et al, 2013                                                                                     
Controlled pilot 
trial
Sample size: 40 - (20 per group)                                                
Age range: 30-65 yrs                             
Gender: 33 female, 1 male
Shiatsu versus home education 
booklet                                                  
Shaitsu:  50 mins 2 x/week for 8 
weeks                                    
Control: wait listed for 8 weeks                       
Total MT dose: 13 hrs 20
Pain: VAS, PPT on 18  points                                                            
Sleep: PSQI                                                                                                                            
Mood: STAI                                                                                      




et al, 2011a                                                        
RCT
Sample size: EG = 30, CG = 29.         
Age range: 18-65 yrs                                           
Gender: F:M  EG = 94%:6%  
CG = 96%:4%
Massage-myofascial release therapy 
versus sham magnetotherapy.                                                   
90 minute session 1 x/week for 20 
weeks.                                              
Total MT dose: 30 hrs
Pain: VAS, algometry on 18 tender sites 
(painful y/n at 4kg).                                                                                             
Sleep: PSQI.                                                                                                                 
Mood: STAI, BDI                                                                                                       




et al, 2011b                                                          
RCT
Sample size: EG = 46, CG =  
46.                                                  
Age range: 16-65yrs.                                  
Gender: 100% female
CST versus sham magnetotherapy                                               
1 hour session 2 x/week for 20 
weeks.                                             
Total MT dose: 40 hrs 
Pain: pressure algometry on 18 tender sites.                                                                            
Sleep: nil                                                                                                                
Mood: nil                                                                                                                   
GMI: CGI-S (researcher measured). CGI-I 
(patient rated)                                                                                              




et al,  2011c                                                                               
Single blind 
clinical trial nested 
in an experimental 
study. 
Sample size: EG = 45, CG = 41                                            
Age range: 45-65 yrs                                
Gender: ?
MFR versus sham ultrasound and 
shortwave.                                                                                      
1 hour session 2 x/week for 20 
weeks.                                                          
Total MT dose: 40hrs 
Pain: algometry at 18 points.  McGill pain 
questionnaire.                                                           
Sleep: nil                                                          
Mood: nil                                                                                                                                                 
GMI: FIQ, CGI-S & CGI-I both patient 
rated.                                                









Sample size: EG = 43, CG =  41                                                    
Age range: 34-63 yrs                                                    
Gender: 81 female, 3 male
CST versus sham Ultrasound                                           
CST:  1 hour 2 x/week for 25 weeks  
Control: 30 min 2 x/week                                                      
Total MT dose: 50hrs
Pain: VAS                                                                                 
Sleep: PSQI                                                                                        
Mood: BDI & STAI                                                                      
GMI: SF-36                                                                                     
Other: nil                        
6
O UTCO MES  -  PPT: Pressure point threshold; VAS : visual analogue scale; GMI: Global Measure of Impact; NHP: Nottingham Health Profile; STAI: State Trait Anxiety index; FIQ & FIQ R: Fibromyalgia Impact 
Questionnaire (R = revised); PSQI: Pittsburgh Sleep Quality Index; CES-D: Center for Epidemiological Studies Depression Scale; MPQ - PPI: McGill Pain Questionnaire - Present Pain Intensity; MPQ - PRI: McGill 
Pain Questionnaire - Present Rating Index; POMS : Profile of Mood States; NMQ:  Nordic Musculoskeletal Questionnaire; CRPS-A: Comprehensive Psychopathological Rating Scale - Affective; HRV: Heart Rate 
Variability; BDI: Becks Depression Index; SF-36: Short Form Health Survey - 36; CGI-S : Clinical Global Impression of Severity; CGI-I: Clinical Global Measure of Improvement; CRF-L1: corticotropin releasing 
factor-like immunoreactivity. INTERVENTIO NS - PE: Pilates Exercise; CTM: Connective Tissue Massage; MLDT: Manual Lymphatic Drainage; MFR: Myofascial Release; SM: Swedish Massage; CST: Cranial Sacral 
Therapy; TENS : Transcutaneous Nerve Stimulation RCT: Randomised Controlled Trial; EG: Experimental group; CG: Control Group; SD: Standard deviation
Table 2
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